To determine the molecular basis of the GM2 gangliosidosis 0 variant, we constructed a three-dimensional structure of the human β-hexosaminidase β-subunit by homology modeling. It is composed of ...

For individuals with Tay-Sachs disease that lack this enzyme, the fatty substance of GM2 ganglioside accumulates in the brain and leads to the symptoms of the disease. Skip to content.

Since its clinical description in 1881, Tay-Sachs disease has had almost totemic significance as a cruel and relentless genetic condition that destroys the developing brain of babies and young ...

Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial.

Gene transfer alters the neurodegenerative course of GM2 gangliosidosis The article by Dr. María Begona Cachon-Gonzalez et al. is published in Current Gene Therapy, Volume 18, 2018 ...

In this phase III EORTC 18961 trial, 1314 patients with stage II melanoma (primary melanoma thicker than 1.5 mm, T3-4N0M0; AJCC Stage II) were randomized to either vaccination with GM2-KLH-QS21 ...

In this phase III EORTC 18961 trial, 1314 patients with stage II melanoma (primary melanoma thicker than 1.5 mm, T3-4N0M0; AJCC Stage II) were randomized to either vaccination with GM2-KLH-QS21 ...

NEW YORK and DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives ...

Background: In the largest adjuvant phase III study in stage II melanoma to date, EORTC 18961 assessed the efficacy and toxicity of ganglioside GM2-KLH/QS-21 vaccination versus observation (OBS).